EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications

Alaa A A Aljabali iD, Kenneth Lundstrom, Altijana Hromić-Jahjefendić, Nawal Abd El-Baky iD, Debaleena Nawn, Sk Sarif Hassan iD, Alberto Rubio-Casillas iD, Elrashdy M Redwan iD, Vladimir N Uversky iD

Viruses · 15.07.2025 · 17 (7) · 985

DOI: 10.3390/v17070985 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 15.07.2025. Verfasst von Alaa A A Aljabali und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan. Hauptthemen laut MEDLINE: Immune Evasion, COVID-19, SARS-CoV-2, Evolution, Molecular. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Narrative review synthesizes the most current literature on the SARS-CoV-2 XEC variant, focusing on its genomic evolution, immune evasion characteristics, epidemiological dynamics, and public health implications. To achieve this, we conducted a structured search of the literature of peer-reviewed articles, preprints, and official surveillance data from 2023 to early 2025, prioritizing virological, clinical, and immunological reports related to XEC and its parent lineages. Defined by the distinctive spike protein mutations, T22N and Q493E, XEC exhibits modest reductions in neutralization in vitro, although current evidence suggests that mRNA booster vaccines, including those targeting JN.1 and KP.2, retain cross-protective efficacy against symptomatic and severe disease. The XEC strain of SARS-CoV-2 has drawn particular attention due to its increasing prevalence in multiple regions and its potential to displace other Omicron subvariants, although direct evidence of enhanced replicative fitness is currently lacking. Preliminary analyses also indicated that glycosylation changes at the N-terminal domain enhance infectivity and immunological evasion, which is expected to underpin the increasing prevalence of XEC. The XEC variant, while still emerging, is marked by a unique recombination pattern and a set of spike protein mutations (T22N and Q493E) that collectively demonstrate increased immune evasion potential and epidemiological expansion across Europe and North America. Current evidence does not conclusively associate XEC with greater disease severity, although additional research is required to determine its clinical relevance. Key knowledge gaps include the precise role of recombination events in XEC evolution and the duration of cross-protective T-cell responses. New research priorities include genomic surveillance in undersampled regions, updated vaccine formulations against novel spike epitopes, and long-term longitudinal studies to monitor post-acute sequelae. These efforts can be augmented by computational modeling and the One Health approach, which combines human and veterinary sciences. Recent computational findings (GISAID, 2024) point to the potential of XEC for further mutations in under-surveilled reservoirs, enhancing containment challenges and risks. Addressing the potential risks associated with the XEC variant is expected to benefit from interdisciplinary coordination, particularly in regions where genomic surveillance indicates a measurable increase in prevalence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune EvasionCOVID-19SARS-CoV-2Evolution, MolecularHumansPublic HealthSpike Glycoprotein, CoronavirusGenome, ViralMutation

Stichwörter der Autor:innen

Omicron sublineageSARS-CoV-2XEC variantimmune evasionpandemic preparednessvaccine efficacy

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
  • PanTherapeutics, Rte de Lavaux 49, CH1095 Lutry, Switzerland.
  • Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Hrasnicka Cesta 15, 71000 Sarajevo, Bosnia and Herzegovina.
  • Protein Research Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab City, Alexandria P.O. Box 21934, Eg…
  • Indian Research Institute for Integrated Medicine (IRIIM), Unsani, Howrah 711302, West Bengal, India.
  • Department of Mathematics, Pingla Thana Mahavidyalaya, Maligram, Paschim Medinipur 721140, West Bengal, India.

ORCID-Profile: Alaa A A Aljabali, Nawal Abd El-Baky, Sk Sarif Hassan, Alberto Rubio-Casillas, Elrashdy M Redwan, Vladimir N Uversky

Zitieren

APA

Aljabali, A. A. A., Lundstrom, K., Hromić-Jahjefendić, A., El-Baky, N. A., Nawn, D., Hassan, S. S., Rubio-Casillas, A., Redwan, E. M., & Uversky, V. N. (2025). The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications. Viruses, 17(7), 985. https://doi.org/10.3390/v17070985

Vancouver

Aljabali AAA, Lundstrom K, Hromić-Jahjefendić A, El-Baky NA, Nawn D, Hassan SS, et al. The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications. Viruses. 2025;17(7):985. doi:10.3390/v17070985

BibTeX
@article{Aljabali2025,
  author = {Aljabali, Alaa A A and Lundstrom, Kenneth and Hromić-Jahjefendić, Altijana and El-Baky, Nawal Abd and Nawn, Debaleena and Hassan, Sk Sarif and Rubio-Casillas, Alberto and Redwan, Elrashdy M and Uversky, Vladimir N},
  title = {The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications},
  journal = {Viruses},
  year = {2025},
  volume = {17},
  number = {7},
  pages = {985},
  doi = {10.3390/v17070985}
}
Kostenlos starten →